Equities analysts expect Guardant Health, Inc. (NASDAQ:GH) to post $77.75 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Guardant Health’s earnings, with the lowest sales estimate coming in at $75.07 million and the highest estimate coming in at $81.30 million. Guardant Health reported sales of $62.90 million during the same quarter last year, which indicates a positive year-over-year growth rate of 23.6%. The company is scheduled to report its next quarterly earnings report after the market closes on Wednesday, February 24th.
According to Zacks, analysts expect that Guardant Health will report full-year sales of $285.69 million for the current year, with estimates ranging from $283.34 million to $289.70 million. For the next financial year, analysts forecast that the company will report sales of $382.36 million, with estimates ranging from $374.10 million to $390.45 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Guardant Health.
A number of research analysts have issued reports on the company. Zacks Investment Research upgraded Guardant Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 6th. William Blair reiterated an “outperform” rating on shares of Guardant Health in a research report on Thursday, November 12th. Canaccord Genuity boosted their price target on Guardant Health from $145.00 to $170.00 in a research report on Tuesday, January 12th. Smith Barney Citigroup boosted their price target on Guardant Health from $145.00 to $155.00 in a research report on Wednesday, December 16th. Finally, BTIG Research boosted their price target on Guardant Health from $132.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, December 17th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $148.70.
In other news, COO Amirali Talasaz sold 201,861 shares of the company’s stock in a transaction on Friday, February 5th. The stock was sold at an average price of $161.76, for a total transaction of $32,653,035.36. Following the completion of the sale, the chief operating officer now directly owns 2,380,745 shares of the company’s stock, valued at $385,109,311.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Stanley J. Meresman sold 4,934 shares of the stock in a transaction on Wednesday, February 10th. The shares were sold at an average price of $162.71, for a total value of $802,811.14. Following the completion of the transaction, the director now owns 8,993 shares of the company’s stock, valued at approximately $1,463,251.03. The disclosure for this sale can be found here. Insiders sold a total of 981,391 shares of company stock worth $156,505,110 in the last three months. Company insiders own 13.00% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley boosted its holdings in shares of Guardant Health by 5.6% in the third quarter. Morgan Stanley now owns 6,310,578 shares of the company’s stock worth $705,397,000 after buying an additional 335,960 shares during the period. BlackRock Inc. boosted its holdings in shares of Guardant Health by 6.8% in the fourth quarter. BlackRock Inc. now owns 5,323,941 shares of the company’s stock worth $686,151,000 after buying an additional 338,191 shares during the period. Credit Suisse AG boosted its holdings in shares of Guardant Health by 10.6% in the fourth quarter. Credit Suisse AG now owns 1,640,318 shares of the company’s stock worth $211,404,000 after buying an additional 157,003 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Guardant Health by 8.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,432,374 shares of the company’s stock worth $184,604,000 after buying an additional 117,511 shares during the period. Finally, Bamco Inc. NY boosted its holdings in shares of Guardant Health by 2.9% in the fourth quarter. Bamco Inc. NY now owns 1,089,983 shares of the company’s stock worth $140,477,000 after buying an additional 31,218 shares during the period. Institutional investors own 84.85% of the company’s stock.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Article: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.